What are the fundraising trends in the cell therapy market?
In our cell therapy market deck, you will find everything you need to understand the market
SUMMARY
We analyzed publicly disclosed equity rounds raised by pure-play cell therapy companies across full-year 2024, full-year 2025, and year-to-date 2026. The analysis includes companies focused on cell-based medicinal products used as drugs, including CAR-T, engineered immune cells, allogeneic therapies, autologous therapies, regenerative cell therapies, and late-stage cell therapies.
The cell therapy market went through a sharp reset in 2025 after an unusually strong 2024. Funding fell from about $3.55B in 2024 to about $1.63B in 2025, even though deal count increased from 25 to 32. That means the market did not lose activity; it lost check size.
Year-to-date 2026 looks stronger than the comparable period in 2025. Cell therapy companies raised about $1.53B through early July 2026, compared with about $617M over the same early-year window in 2025. The recovery is real, but it is concentrated in a small number of large rounds.
The biggest change in the cell therapy market is capital concentration. In year-to-date 2026, the top 10 rounds captured about 90% of all capital, and the bottom half of deals captured less than 10%. That is a winner-takes-most funding structure, not a broad easy-money environment.
Allogeneic Cell Therapies became the clearest capital magnet in year-to-date 2026. The category captured about 51% of capital from only 20% of deals, showing that investors are paying a premium for scalable, off-the-shelf cell therapy approaches when clinical or commercial validation is credible.
CAR T Therapies remain the most active category by deal count, but the strongest CAR-T signal is no longer generic CAR-T enthusiasm. Investor attention is shifting toward in vivo CAR-T, autoimmune disease, solid tumors, and approaches that reduce manufacturing or delivery friction.
Capital is moving back toward later-stage and validation-stage companies. In 2025, Seed and Series A rounds captured about 42% of capital, helped by several large platform launches. In year-to-date 2026, late-stage, growth, and Series B-plus financings captured about 82% of capital.
North America remains the center of cell therapy funding, with about 77% of year-to-date 2026 capital. Asia-Pacific is gaining meaningful momentum, reaching about 23% of year-to-date 2026 capital, while Europe has no qualifying deal in the current partial-year window.
New startups are still entering the cell therapy market, but they are not driving most of the dollars. First financings represented 15% of year-to-date 2026 deals and only 8.5% of capital, down from 22% of deals and 28% of capital in full-year 2025.
The best interpretation is that the cell therapy market remains investable but has become much more selective. Investors are no longer asking only whether cell therapy can work; they are asking whether a company can scale, manufacture, deliver, regulate, and commercialize a therapy in a way that justifies the cost of development.
This chart, featured in our cell therapy market deck, shows how market revenue is split across customer segments in the cell therapy market
Is more or less capital going into the cell therapy market?
Less capital went into the cell therapy market in 2025 than in 2024, but the freshest 2026 signal points to a selective rebound. Full-year funding fell from about $3.55B in 2024 to about $1.63B in 2025, which is a decline of roughly 54%. That full-year comparison is the cleaner structural read because both years are complete.
The 2025 decline should not be interpreted as investor abandonment. Deal count increased from 25 deals in 2024 to 32 deals in 2025, so more companies received capital, but the checks became much smaller. Average round size fell from about $142M to about $51M, while median round size fell from $112M to $45M.
So far in 2026, the cell therapy market looks much stronger than it did over the same early-year period in 2025. Companies raised about $1.53B through early July 2026, compared with about $617M over the comparable period in 2025. That is roughly a 2.5x increase in capital over the freshest comparison window.
The caution is concentration. In year-to-date 2026, the top 3 rounds captured about 49% of all capital and the top 10 captured about 90%. The rebound is real, but it is not broad-based easy funding; it is a reopening for selected companies that look scalable, clinically mature, strategically differentiated, or close to commercialization.
For the full company-by-company view behind these totals, see the full cell therapy market report.
Is cell therapy funding activity driven by more deals or larger rounds?
Cell therapy funding activity is currently being driven more by larger rounds than by deal count alone. Deal count rose from 12 deals over the comparable early-2025 period to 20 deals in year-to-date 2026, but capital rose from about $617M to about $1.53B. Deals increased by roughly two-thirds, while capital rose by roughly 2.5x.
The full-year 2025 comparison tells the opposite story and explains why the current rebound matters. In 2025, the cell therapy market had more deals than 2024, but total capital fell sharply. That means 2025 was driven by more, smaller financings rather than larger conviction rounds.
The year-to-date 2026 pattern has shifted back toward large checks. Artiva raised $300M, Orca Bio raised $250M, Allogene raised about $200M, MEDIPOST raised $140M, Century raised $135M, and CREATE Medicines raised $122M. Those six financings alone explain why the current capital total looks much stronger than the comparable 2025 period.
This distinction matters because the cell therapy market is capital-intensive. A market dominated by $5M to $20M rounds would indicate runway extensions and narrow clinical steps. A market with repeated $100M-plus rounds indicates that investors are again willing to fund manufacturing, clinical operations, regulatory execution, and commercialization preparation.
Is cell therapy capital moving toward later-stage or earlier-stage companies?
Cell therapy capital is moving back toward later-stage and validation-stage companies in 2026, after 2025 briefly opened a larger window for earlier-stage platform formation. In 2024, late-stage Series B-plus and growth financings represented about 86% of capital. In 2025, Seed and Series A rounds captured about 42% of capital. In year-to-date 2026, late-stage and growth financings are back to about 82% of capital.
The 2025 early-stage signal was real, but it was not a return to cheap discovery-stage funding. Series A was the largest stage by dollars in 2025 because several expensive platform launches raised large rounds, including Dispatch Bio, Stylus Medicine, Azalea Therapeutics, Somite AI, and other next-wave cell therapy companies.
Year-to-date 2026 is much more validation-weighted. Growth equity alone accounts for about $848M, or 56% of capital. Series D+ adds another $250M through Orca Bio. Series A contributes only about $144M, or less than 10% of capital.
The practical interpretation is that investors are not primarily rewarding early scientific possibility right now. The largest dollars are moving toward companies with clinical validation, public-market access, allogeneic scale logic, autoimmune expansion, in vivo delivery promise, or commercialization readiness.
This chart, featured in our cell therapy market deck, compares the main business model options for cell therapy biotech companies
Is the cell therapy market maturing or still experimental?
The cell therapy market is maturing, but it is not mature in the way a conventional pharmaceutical category is mature. It is maturing from broad platform experimentation into selective validation financing, where investors reward companies that can show scalability, clinical direction, manufacturability, or commercial proximity.
In 2024, the market was already validation-led: about 86% of capital went to Series B-plus and growth financings, and 21 of 25 deals were above $50M. In 2025, the market looked more experimental because deal count rose, first financings increased, and Series A became the largest stage by number of deals.
But the 2025 experimentation was not random. New money clustered around in vivo CAR-T, AI-designed cell therapies, regenerative platforms, solid-tumor immune-cell engineering, and new companies backed by serious specialist investors. That is a sign of targeted experimentation, not speculative category sprawl.
Year-to-date 2026 has tilted back toward maturity. Growth equity and Series D+ together account for about 72% of capital, and the largest rounds went to companies such as Artiva, Orca Bio, Allogene, MEDIPOST, Century, and CREATE Medicines. These are not generic concept-stage startups; they are validation, scale, or commercialization stories.
The honest interpretation is that investors broadly accept that cell therapies can work biologically. The remaining question is which cell architectures can scale, which indications justify the manufacturing burden, and which companies can turn clinical promise into durable, reproducible, commercially realistic products.
Are new startups still entering the cell therapy market?
Yes, new startups are still entering the cell therapy market, but new-company formation is selective rather than broad-based. In 2024, first financings represented only 8% of deals and about 4% of capital. In 2025, first financings rose to about 22% of deals and 28% of capital. In year-to-date 2026, they fell back to 15% of deals and only 8.5% of capital.
The strongest new-entrant signal came in 2025. Dispatch Bio raised $216M as a first financing, Stylus Medicine launched with $85M, Azalea Therapeutics launched with $82M, Somite AI raised $47M, and several smaller first financings appeared across Europe and Asia-Pacific.
Year-to-date 2026 is more cautious. Cytotheryx raised $60M, Vivacta Bio raised more than $50M, and Waypoint Bio raised $20M, but most dollars still went to follow-on financings. First financings represented only 3 of 20 deals and about $130M of the $1.53B raised.
The rule is clear: the cell therapy market is open to new startups only when the company brings more than a generic next-generation cell therapy claim. New entrants need a credible in vivo thesis, differentiated platform, manufacturing advantage, strong syndicate, specific clinical wedge, or a route around known delivery bottlenecks.
For a deeper view of which new entrants are appearing across CAR-T, allogeneic, regenerative, and engineered immune-cell categories, see the cell therapy market deck.
Are more investors entering the cell therapy market?
More investors appeared across the cell therapy market in 2025 than in 2024, but the 2026 signal is more concentrated and less clearly expansionary. The number of disclosed unique investors increased from roughly 90 in 2024 to roughly 109 in 2025, even as the number of unique tier-1 investors fell from about 45 to 21.
That means 2025 had broader participation overall, but fewer top-tier specialist investors than 2024. The market was wider by disclosed investor count, but thinner by elite conviction and check size.
Year-to-date 2026 already shows roughly 60-plus disclosed investors and about 28 tier-1 investors, which is meaningful for a partial-year window. Names such as RA Capital, Venrock, Qiming, OrbiMed, F-Prime, General Catalyst, Lux, ARCH, Blackstone, Viking, TCGX, and Lightspeed appear in strategically important rounds.
The repeat-investor signal is still narrow. Qiming, RA Capital, and Venrock are the only named investors with more than one qualifying deal so far in 2026. The cell therapy market is therefore attracting serious investors, but not a flood of generalists willing to fund the average company.
This chart, featured in our cell therapy market deck, shows annual funding in cell therapy startups
Are top investors getting more or less active in cell therapy?
Top investors became less broadly active in the cell therapy market in 2025 than they were in 2024, but they remain highly influential in 2026 where the strongest rounds are concerned. In 2024, Alexandria appeared in 4 deals, The Column Group in 3, Cormorant in 3, and RA Capital in 3. In 2025, the repeat-investor list became broader but thinner, with Cormorant at 3 deals and many top investors at 2 deals.
The decline in tier-1 investor breadth in 2025 is important. Unique tier-1 investors fell from roughly 45 in 2024 to 21 in 2025, even though total deal count increased from 25 to 32. That means higher deal count did not equal stronger top-tier conviction.
Year-to-date 2026 shows top investors returning selectively. RA Capital and Venrock appear in Century and Artiva. Qiming appears in OriCell and Vivacta. ARCH appears in CREATE Medicines, OrbiMed appears in Vivacta, F-Prime appears in Immuneel, and Blackstone, Viking, EcoR1, Samsara, TCGX, Lightspeed, General Catalyst, and Lux all show up in meaningful financings.
The better interpretation is that top investors are not spraying capital across the cell therapy market. They are concentrating activity in autoimmune cell therapy, allogeneic platforms, in vivo CAR-T, late-stage commercialization readiness, and solid-tumor differentiation.
Which cell therapy subcategories are gaining momentum?
The subcategories gaining the most momentum in the cell therapy market are Allogeneic Cell Therapies, in vivo-oriented CAR T Therapies, and selected Late Stage Cell Therapies. The strongest current evidence is Allogeneic Cell Therapies, which captured about $775M, or 51% of year-to-date 2026 capital, from only 4 deals.
Allogeneic momentum is not just theoretical. Century raised $135M, MEDIPOST raised $140M, Allogene raised about $200M, and Artiva raised $300M. Those rounds show that investors are willing to fund off-the-shelf, scalable cell therapy approaches when clinical direction and commercial logic are credible.
CAR T Therapies are also gaining momentum, but the momentum is inside specific versions of CAR-T rather than the whole category equally. In 2025, CAR T Therapies led both deal count and capital, with 13 deals and about $569M. In year-to-date 2026, the category has 6 deals and about $324M.
The strongest CAR-T momentum is around in vivo delivery, autoimmune disease, and solid tumors. CREATE, Vivacta, Waypoint, OriCell, Lyell, and Immuneel all fit parts of that thesis. Investors still like CAR-T, but they increasingly want CAR-T that can become less logistically constrained and more commercially expandable.
Late Stage Cell Therapies also gained visibility because Orca Bio raised $250M in year-to-date 2026. One deal is not enough to prove broad category acceleration, but it is enough to confirm that commercialization-ready cell therapy assets can still unlock very large checks.
For more detail on category-level funding momentum, see the market report covering cell therapy subcategories.
Which cell therapy subcategories are losing momentum?
The subcategories losing momentum in the cell therapy market are Autologous Cell Therapies, smaller Regenerative Cell Therapies, and non-CAR engineered immune-cell approaches outside a few strong exceptions. The clearest weak 2026 signal is Autologous Cell Therapies: 3 deals raised only about $6.8M, or less than 1% of all capital.
Autologous Cell Therapies looked healthier in 2025 because Aspen Neuroscience raised $115M and Innovacell raised about $48M, giving the category $163M for the year. But in year-to-date 2026, the category consists mostly of small public or bridge-style financings from BrainStorm and BioCardia.
Engineered Immune Cells also look weaker so far in 2026 outside allogeneic NK and CAR-T-adjacent stories. The category raised about $331M across 6 deals in 2025, helped by Dispatch Bio, Anocca, NK CellTech, Rui Therapeutics, Captain T Cell, and Pan Cancer T. In year-to-date 2026, the category has only one deal, Ernexa’s $10.5M public offering.
Regenerative Cell Therapies are not losing activity, but they are losing capital intensity relative to allogeneic and late-stage categories. The category raised about $357M in 2025 and about $159M in year-to-date 2026, but its 2026 average deal size is only about $32M.
This chart, featured in our cell therapy market deck, shows how Legend Biotech is winning in cell therapy
Which regions are gaining momentum in cell therapy funding?
Asia-Pacific is gaining the clearest regional momentum in the cell therapy market, while North America remains the dominant funding region. In 2025, Asia-Pacific appeared with 9 deals and about $179M after being absent from the 2024 regional split. In year-to-date 2026, Asia-Pacific has 6 deals and about $352M, or 23% of capital.
The Asia-Pacific signal is not just a string of small rounds. MEDIPOST raised $140M, OriCell raised $70M, Vivacta raised more than $50M, Regend raised about $50M, iRegene raised about $30M, and Immuneel raised about $12M. That mix covers late-stage stem-cell therapy, CAR-T, in vivo CAR-T, regenerative medicine, and regional commercialization-linked programs.
North America is also gaining in absolute dollars compared with the same early-year period in 2025. North America raised about $600M over the comparable 2025 period and about $1.17B so far in 2026. But North America’s share has declined from about 97% to about 77% because Asia-Pacific became much more visible.
So the regional story is not that North America is weakening in absolute terms. The story is that Asia-Pacific is becoming a more credible second funding pole, especially for CAR-T, regenerative, and late-stage regional cell therapy companies.
Which regions are losing momentum in cell therapy funding?
Europe is losing momentum in the cell therapy market relative to both North America and Asia-Pacific. In 2024, Europe had only 3 deals but captured about $635M, mostly because of Autolus’s $550M financing. In 2025, Europe increased to 6 deals but captured only about $99M.
That means Europe had more company activity in 2025, but far less capital intensity. The region’s 2024 funding strength was heavily dependent on one unusually large transaction rather than broad regional depth.
The 2026 signal is weaker. Through early July 2026, the qualifying list contains no European financings, while North America has 14 deals and Asia-Pacific has 6. Because the year is incomplete, this should be treated as a preliminary signal, but the near-term direction is clearly negative.
Latin America, the Middle East, and Africa remain absent from the qualifying financing evidence across the provided periods. That absence is structurally meaningful because the cell therapy market depends on GMP manufacturing, specialist clinical networks, regulatory sophistication, and deep biotech capital pools.
Is the cell therapy market becoming more global or more regionally concentrated?
The cell therapy market is becoming more global by deal formation, but capital remains regionally concentrated in North America. Full-year 2025 was more global than 2024 because Asia-Pacific appeared with 9 deals and Europe had 6 deals, while North America’s deal share fell to about 53%. But North America still captured about 83% of 2025 capital.
Year-to-date 2026 continues that pattern. Asia-Pacific has 6 of 20 deals and 23% of capital, which is a real presence. MEDIPOST, OriCell, Vivacta, Regend, iRegene, and Immuneel show that Asia-Pacific is not merely producing tiny exploratory financings.
North America remains the capital center because it has the deepest public-market and specialist-venture financing channels. Artiva, Orca Bio, Allogene, Century, CREATE, Cytotheryx, Lyell, Waypoint, and Syntax Bio show that the largest checks still cluster in North American funding ecosystems.
The accurate conclusion is that the cell therapy market is globalizing from a North American core. Asia-Pacific is gaining real momentum, Europe is inconsistent, and Latin America, the Middle East, and Africa are not yet visible as qualifying financing hubs.
For the regional breakdown behind this interpretation, see the deeper analysis of the cell therapy market.
This chart, featured in our cell therapy market deck, shows how CAR-T approvals have driven growth in the cell therapy market over time
Is cell therapy capital moving toward proven winners or new opportunities?
Cell therapy capital is moving more toward proven winners in 2026, after 2025 created a temporary opening for new opportunities. In year-to-date 2026, follow-on financings account for 85% of deals and about 91.5% of capital. First financings account for only 15% of deals and 8.5% of capital.
That is a major shift from 2025. Full-year 2025 first financings accounted for about 22% of deals and 28% of capital, helped by large launches such as Dispatch Bio, Stylus Medicine, Azalea Therapeutics, Somite AI, StemSight, DeliNova, and T-CURX.
Year-to-date 2026 is much more winner-oriented. The largest financings went to Artiva, Orca Bio, Allogene, MEDIPOST, Century, CREATE, OriCell, Cytotheryx, Regend, Lyell, and Vivacta. Most of these are not raw company-formation stories; they involve public companies, late-stage programs, autoimmune expansion, allogeneic scale-up, or validated investor syndicates.
The cell therapy market is not closed to new opportunities, but new opportunities must look unusually credible. The default dollar flow is toward companies with prior validation, visible clinical direction, scalable architecture, or strategic positioning.
Is the cell therapy market becoming winner-takes-most?
Yes, the cell therapy market is becoming winner-takes-most in capital allocation, especially in year-to-date 2026. The top 3 rounds captured about 49% of 2026 capital so far, the top 5 captured about 67%, and the top 10 captured about 90%. The bottom half of deals captured only about 10% of capital.
The 2025 full-year market was also concentrated, but less extreme. In 2025, the top 10 deals captured about 65% of capital, and the bottom half of deals captured about 17%. In 2024, the top 10 captured about 70%, and the bottom half captured about 20%.
This concentration matters because cell therapy companies need large amounts of capital to execute properly. A company raising $2M to $10M is often only extending runway or funding a narrow clinical step. A company raising $100M to $300M can fund manufacturing, clinical operations, regulatory work, and commercialization preparation.
The cell therapy market is not winner-takes-all because many modalities and regions still receive some capital. But it is clearly winner-takes-most, with the perceived best companies absorbing the overwhelming majority of dollars.
Is the next wave of cell therapy winners becoming visible?
Yes, the next wave of winners in the cell therapy market is becoming visible, but the signal is stronger at the theme level than at the individual-company level. The visible themes are allogeneic cell therapy, in vivo CAR-T, autoimmune immune reset, late-stage commercialization-ready therapies, and regenerative platforms with clearer clinical paths.
Allogeneic companies are the clearest near-term winners by capital. Artiva, Allogene, Century, and MEDIPOST together account for more than half of year-to-date 2026 capital. That does not prove every allogeneic approach will work, but it shows where investors currently believe scalability and clinical relevance intersect.
In vivo CAR-T is also becoming a visible next-wave theme. CREATE raised $122M, Vivacta raised more than $50M, Waypoint raised $20M, and OriCell raised $70M. Prior 2025 financings for Umoja, Stylus, Azalea, DeliNova, T-CURX, MagicRNA, and Vyriad show that the theme was already forming before 2026.
Autoimmune disease is another emerging winner. Across 2024, 2025, and 2026, autoimmune indications appear repeatedly across CAR-T, allogeneic, NK, Treg, and in vivo platforms. That matters because autoimmune disease expands cell therapy beyond oncology and gives investors a much larger commercial imagination.
The caution is that visibility is not proof. The next wave is visible because capital is clustering around specific technical and commercial theses; the actual winners will be the companies that convert those theses into durable clinical benefit, acceptable safety, reproducible manufacturing, and realistic delivery economics.
For more on which companies and modalities are becoming visible in the next wave, see the full market view on cell therapy winners.
As this chart shows, and as featured in our cell therapy market deck, search interest in stem cell therapy has been rising steadily
Is the cell therapy funding landscape fragmenting or consolidating?
The cell therapy funding landscape is fragmenting by modality and geography, but consolidating by capital intensity. More types of companies and more regions are appearing, especially across 2025 and 2026, but the largest dollars are concentrating into fewer high-conviction companies.
The fragmentation is visible in the 2025 deal mix. There were 32 deals across CAR-T, regenerative, engineered immune-cell, allogeneic, and autologous categories. Asia-Pacific and Europe both contributed meaningful deal count, and the market included in vivo CAR-T, TCR-T, NK cells, iPSC-derived therapies, reproductive cell therapy, B-cell medicines, and other approaches.
The consolidation is visible in the 2026 dollar flow. The top 10 deals captured about 90% of capital, Allogeneic Cell Therapies captured 51% of capital from only 4 deals, and the bottom half of deals captured less than 10% of capital. Scientific approaches are multiplying, but financing power is narrowing.
This is the defining tension in the cell therapy market. The market can look innovative and diverse by company count while behaving like a concentrated validation market by dollars.
Where is investor attention shifting in cell therapy?
Investor attention in the cell therapy market is shifting toward scalability, autoimmune disease, in vivo engineering, allogeneic platforms, and commercialization readiness. The clearest evidence is the year-to-date 2026 capital mix: Allogeneic Cell Therapies captured about 51% of capital, Late Stage Cell Therapies captured 16%, and several CAR-T financings were tied to in vivo delivery, autoimmune expansion, or solid-tumor differentiation.
The shift away from simple modality enthusiasm is important. Investors are not just funding CAR-T because CAR-T is validated. They are funding CAR-T when the company can argue for a new access model, a new indication, a new delivery route, or a better solid-tumor strategy.
Investor attention is also moving away from smaller autologous regenerative stories unless there is strong clinical or strategic validation. Autologous Cell Therapies raised only about $6.8M so far in 2026 despite three deals, suggesting that individualized, infrastructure-heavy approaches are struggling to attract scaled capital.
The most useful reading rule is this: investor attention has moved from “can a cell therapy work?” to “can this cell therapy scale, reach a large indication, and justify its manufacturing and delivery burden?” Companies that answer that question convincingly are getting large rounds. Companies that do not are raising small extensions or disappearing from the financing map.
For continued tracking of these investor-attention shifts, see the cell therapy market report.
INSIGHTS
The insights below come from reviewing disclosed equity financings in the cell therapy market across full-year 2024, full-year 2025, and year-to-date 2026.
- The cell therapy market’s headline direction depends heavily on whether capital or deal count is weighted more heavily. Deal count rose from 25 in 2024 to 32 in 2025, but capital fell by more than half, proving that more funded companies did not automatically mean a healthier financing environment.
- The 2026 rebound is real but narrow. Capital through early July 2026 is about 2.5x the comparable 2025 period, but the top 10 deals captured about 90% of that capital, which means the recovery is concentrated in a small number of perceived winners.
- The market is moving from modality validation to execution validation. Investors no longer need to be convinced that cell therapies can work biologically; they need to be convinced that a specific company can manufacture, deliver, regulate, and commercialize the therapy at scale.
- The sharp fall in median round size from $112M in 2024 to $45M in 2025 shows that 2025 was not simply a smaller version of 2024. It was a different market structure, with more companies funded but fewer receiving enough capital to materially de-risk expensive development paths.
- Allogeneic Cell Therapies became the clearest 2026 capital magnet because they promise repeatability and scale. A 51% capital share from only 20% of deals shows that investors are paying a premium for off-the-shelf logic when it is paired with credible clinical or commercial direction.
- CAR-T remains active, but the CAR-T market has become internally stratified. The stronger funding signal is not the CAR-T label by itself; it is CAR-T combined with in vivo delivery, autoimmune expansion, solid-tumor strategy, or improved access economics.
- Autologous Cell Therapies show the weakest current capital signal. Three 2026 deals raised less than $7M combined, which suggests many autologous non-oncology companies are being financed as bridge or survival stories rather than category-defining platforms.
- Regenerative Cell Therapies remain broad but not consistently capital-intensive. The category has recurring deal activity across years, but 2026 average deal size is far below allogeneic and late-stage categories, implying that investors still see endpoint, delivery, and adoption risk.
- Late Stage Cell Therapies are not high-frequency, but they command premium dollars when commercialization is plausible. Orca Bio’s $250M financing shows that near-commercial cell therapy assets can still unlock very large checks even in a selective market.
- Public-market access has become a critical financing channel for mature cell therapy companies. Artiva, Allogene, Century, Lyell, BioRestorative, BrainStorm, BioCardia, and Ernexa show that public or quasi-public equity can shape the apparent health of the sector.
- Public offerings should not automatically be read as scientific validation. A large public financing can signal strong investor confidence, but smaller registered directs and private placements often indicate runway extension rather than deep platform endorsement.
- The cell therapy market is globally broadening but not globally equalizing. Asia-Pacific has become meaningful by deal count and capital, but North America still dominates large financings and specialist-investor activity.
- Europe’s role is unstable and highly outlier-dependent. Europe looked strong in 2024 because of Autolus, looked thinner in 2025 despite more deals, and is absent from the 2026 year-to-date list, showing that European cell therapy financing depth is not yet consistent.
- The absence of Latin America, the Middle East, and Africa is structurally meaningful. Cell therapy financing appears to require specialized clinical infrastructure, GMP capacity, regulatory familiarity, and deep life-science capital, which remain concentrated in North America, Asia-Pacific, and parts of Europe.
- The market is becoming winner-takes-most rather than winner-takes-all. Many companies still raise money, but only a small subset receives enough capital to materially change clinical or commercial trajectory.
- The $50M threshold functions as a credibility line in the cell therapy market. Rounds above that level tend to indicate strategic validation or a meaningful clinical plan, while many sub-$20M rounds look more like milestone bridges.
- Early-stage labels can be misleading in cell therapy. A Series A can be a large platform launch or a small regional financing, so stage alone is less informative than round size, syndicate quality, technical ambition, and clinical path.
- Investor attention is migrating from ex vivo complexity toward in vivo engineering. The repeated financings of in vivo CAR-T and in vivo immune-programming companies across 2025 and 2026 indicate that reducing manufacturing and logistics burden is now a central investment thesis.
- Autoimmune disease is no longer a secondary indication story. Repeated funding for autoimmune-linked cell therapies across CAR-T, NK, allogeneic, Treg, and in vivo approaches suggests investors see immune reset as one of the largest expansion paths for the market.
- The strongest current evidence favors companies that combine three features: a validated biological mechanism, a scalable delivery or manufacturing model, and a large commercial indication. Missing one of those features usually pushes a company toward smaller financing.
- The cell therapy market should be forecast as lumpy rather than smooth. Long gaps between deals, large top-round shares, and repeated dependence on public-market windows mean quarterly or half-year totals can swing dramatically based on a few financings.
This chart, featured in our cell therapy market deck, shows how CAR-T cell therapy technology has evolved over time
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this cell therapy funding tracker by reviewing publicly disclosed equity rounds raised by pure-play cell therapy companies across full-year 2024, full-year 2025, and year-to-date 2026. A company counts as pure-play when more than 80% of its activity is dedicated to therapeutic cell products used as drugs to treat disease.
The tracker includes living-cell medicinal products such as CAR-T therapies, other engineered immune-cell therapies, allogeneic cell therapies, autologous cell therapies, regenerative cell therapies, and late-stage cell therapies. It excludes standard stem-cell transplants, minimally manipulated surgical cell preparations, manufacturing-only providers, research tools, CDMOs, generic equipment suppliers, and companies whose main business is not a therapeutic cell product.
We applied four core filters. First, we only included equity rounds, including public offerings and PIPEs when the company itself raised primary capital. Second, we only counted disclosed rounds of $300K or more. Third, we only kept pure-play companies under the 80% rule. Fourth, every included financing had to be supported by a direct company announcement, press release, investor-relations page, tier-1 media report, specialized industry publication, or relevant regional funding source.
We excluded grants, debt-only financings, acquisitions, M&A-related consideration, partnerships without primary equity, undisclosed-size rounds, and financings where the equity component could not be isolated. Undisclosed-amount rounds are excluded because they would distort dollar-based metrics such as total capital, average round size, median round size, category share, and concentration ratios.
The final analysis uses announcement month and year for timing, converts non-US rounds into approximate US dollars where needed, and preserves stage, category, geography, investor, and source information for every qualifying financing. Publicly undisclosed private rounds are necessarily missing, which is a limitation of any public-only tracker.
Related blog posts
- The latest progress in the cell therapy market
- What is the latest news in the cell therapy market?
- What is the true size of the cell therapy market?
- What are the latest funding developments in the cell therapy market?
- How funding activity has evolved in the cell therapy market
- Which companies have raised the most funding in the cell therapy market?
- Which companies are the most valued in the cell therapy market?
